Amedisys (NASDAQ:AMED) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Key Points

• Amedisys (NASDAQ:AMED) reported a quarterly earnings per share (EPS) of $1.54, exceeding estimates by $0.15.
• Stock prices saw a 0.6% increase, reaching $97.52, with a market capitalization of $3.20 billion.
• Major institutional investors have significantly increased their holdings in Amedisys, with AQR Capital Management boosting its stake by 98.3%.

Amedisys (NASDAQ:AMED - Get Free Report) issued its earnings results on Tuesday. The health services provider reported $1.54 EPS for the quarter, topping the consensus estimate of $1.39 by $0.15, Zacks reports. Amedisys had a return on equity of 12.91% and a net margin of 3.56%. The business had revenue of $621.86 million during the quarter, compared to the consensus estimate of $614.61 million. During the same quarter last year, the company earned $0.98 EPS. The firm's revenue was up 5.2% compared to the same quarter last year.

Amedisys Price Performance

Shares of NASDAQ:AMED traded down $0.09 on Friday, hitting $98.51. The company's stock had a trading volume of 872,139 shares, compared to its average volume of 370,725. The company has a 50-day simple moving average of $96.75 and a 200 day simple moving average of $94.17. Amedisys has a 1 year low of $82.15 and a 1 year high of $99.00. The company has a market capitalization of $3.24 billion, a PE ratio of 38.33, a PEG ratio of 1.33 and a beta of 0.89. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.36 and a quick ratio of 1.29.

Hedge Funds Weigh In On Amedisys

A number of large investors have recently modified their holdings of the company. Empowered Funds LLC raised its holdings in shares of Amedisys by 10.1% during the 1st quarter. Empowered Funds LLC now owns 3,854 shares of the health services provider's stock valued at $357,000 after buying an additional 354 shares in the last quarter. Great Lakes Advisors LLC purchased a new position in shares of Amedisys during the 1st quarter valued at about $214,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Amedisys by 9.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,990 shares of the health services provider's stock valued at $184,000 after buying an additional 176 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Amedisys by 98.3% during the 1st quarter. AQR Capital Management LLC now owns 13,410 shares of the health services provider's stock valued at $1,242,000 after buying an additional 6,646 shares in the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on AMED. Wall Street Zen downgraded Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 24th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $100.00 price target on shares of Amedisys in a report on Wednesday, April 16th.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.